Jahan Azra, Shams Sumaira, Ali Safdar, Samrana Samrana, Ali Amjad, Adhikari Achyut, Sajid Muhammad, Ali Abid, Ali Hamid
Department of Zoology, Abdul Wali Khan University, Mardan 23200, Khyber Pakhtunkhwa, Pakistan.
Department of Physics, University of Swabi, Anbar 23561, Khyber Pakhtunkhwa, Pakistan.
ACS Omega. 2021 Jan 21;6(4):2462-2472. doi: 10.1021/acsomega.0c02261. eCollection 2021 Feb 2.
Liver diseases such as hepatic carcinoma are one of the main health problems worldwide. Herbal drugs are largely used to treat liver injury in the indigenous system of medicine and may provide lead compounds for hepatoprotective drug discovery. The present study is investigated to test the Wall. extract, fraction, and isolate therapeutically active constituents to explore their hepatoprotective, anti-inflammatory, and antioxidant activities. For this purpose, the antioxidant activity of govaniadine, caseadine, caseamine, and protopine was performed by assessing the scavenging events of the stable 2,2-diphenyl-1-picrylhydrazyl. Hepatoprotection of govaniadine was assessed in terms of reduction in serum enzymes (alanine aminotransferase, aspartate transaminase, and alkaline phosphatase) caused by CCl-induced liver injury in rats and by histopathological techniques. All the compounds showed significant antioxidant activity with a percentage inhibition of 92.2, 86.7, 85.3, and 79.7, respectively, compared to propyl gallate 90.3%. Treatment with govaniadine reduced the serum enzyme level down to normal levels in the CCl-treated group while inhibiting the increase of malondialdehyde, and the induction of superoxide dismutase and the glutathione level was upregulated. Histopathology showed ∼47% damage to the liver cells in the CCl-treated group; reduction in this damaged area was found to be better upon using govaniadine. Immunohistochemistry results showed that govaniadine as compared to silymarin has exceedingly decreased the inflammation by halting the CCl-induced activation of hepatic macrophages. In carrageenan-induced paw edema assay, govaniadine significantly alleviated the edema after 1-5 h at a dose of 20 mg/kg (26.00 and 28.5%), 50 mg/kg (22.05 and 27.0%), and 100 mg/kg (20.02 and 25.30%), respectively. The results of our experiments suggest that govaniadine showed antioxidant and hepatoprotective activity in liver injury. The hepatoprotective function of govaniadine may be associated to the scavenging of the free radical and attenuation of oxidative stress as well as inflammatory responses in the liver. Hence, govaniadine may be a lead compound for the hepatoprotective drug discovery process and further research is needed to find out their molecular mechanism of protection.
肝癌等肝脏疾病是全球主要的健康问题之一。草药在传统医学体系中被广泛用于治疗肝损伤,可能为发现具有肝脏保护作用的药物提供先导化合物。本研究旨在测试Wall.提取物、馏分和分离出的治疗活性成分,以探索它们的肝脏保护、抗炎和抗氧化活性。为此,通过评估稳定的2,2-二苯基-1-苦基肼自由基的清除情况,对戈瓦尼定、卡塞定、卡塞明和普罗托品的抗氧化活性进行了检测。通过检测大鼠四氯化碳诱导的肝损伤导致的血清酶(丙氨酸转氨酶、天冬氨酸转氨酶和碱性磷酸酶)水平降低情况以及组织病理学技术,评估了戈瓦尼定的肝脏保护作用。与没食子酸丙酯90.3%相比,所有化合物均表现出显著的抗氧化活性,抑制率分别为92.2%、86.7%、85.3%和79.7%。用戈瓦尼定治疗可使四氯化碳处理组的血清酶水平降至正常水平,同时抑制丙二醛的增加,超氧化物歧化酶的诱导作用增强,谷胱甘肽水平上调。组织病理学显示,四氯化碳处理组肝细胞损伤约47%;使用戈瓦尼定后,发现该损伤区域的减少情况更好。免疫组织化学结果显示,与水飞蓟宾相比,戈瓦尼定通过阻止四氯化碳诱导的肝巨噬细胞活化,极大地减轻了炎症。在角叉菜胶诱导的爪肿胀试验中,戈瓦尼定在剂量为20mg/kg(分别为26.00%和28.5%)、50mg/kg(22.05%和27.0%)和100mg/kg(20.02%和25.30%)时,在1-5小时后显著减轻了肿胀。我们的实验结果表明,戈瓦尼定在肝损伤中表现出抗氧化和肝脏保护活性。戈瓦尼定的肝脏保护功能可能与清除自由基、减轻氧化应激以及肝脏中的炎症反应有关。因此,戈瓦尼定可能是肝脏保护药物发现过程中的先导化合物,需要进一步研究以找出其保护的分子机制。